Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer

Background MET expression and activation appear to be important for initiation and progression of triple-negative breast cancer. Tivantinib (ARQ 197) is an orally administered agent that targets MET, although recent preclinical data suggests the agent may have mechanisms of action that are independe...

Full description

Saved in:
Bibliographic Details
Published in:Invest New Drugs
Main Authors: Tolaney, Sara M., Tan, Sally, Guo, Hao, Barry, William, Van Allen, Eliezer, Wagle, Nikhil, Brock, Jane, Larrabee, Katherine, Paweletz, Cloud, Ivanova, Elena, Janne, Pasi, Overmoyer, Beth, Wright, John J., Shapiro, Geoffrey I., Winer, Eric P., Krop, Ian E.
Format: Artigo
Language:Inglês
Published: Springer US 2015
Subjects:
Phase II Studies
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4608248/
https://ncbi.nlm.nih.gov/pubmed/26123926
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-015-0269-8
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items